Vasosulf Disease Interactions
There are 11 disease interactions with Vasosulf (phenylephrine / sulfacetamide sodium ophthalmic).
- Narrow angles
- Hematologic toxicity
- Hypersensitivity reactions
- Porphyria
- Crystalluria
- Liver disease
- Renal dysfunction
- Urinary obstruction
- BPH
- Cardiovascular
- Diabetes
Ophthalmic sympathomimetics (applies to Vasosulf) narrow angles
Major Potential Hazard, High plausibility. Applicable conditions: Glaucoma (Narrow Angle)
The use of nonspecific ophthalmic sympathomimetic agents is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles. These agents stimulate both alpha-1 and alpha-2 adrenergic receptors, thus topical administration can induce transient mydriasis. In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma. If possible, these agents (except for phenylephrine 2.5% or 10%) should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.
References
- "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough
- (2001) "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals
Topical sulfonamides (applies to Vasosulf) hematologic toxicity
Major Potential Hazard, Low plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes. The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia. Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression. Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.
References
- Barak S, Shaked Y, Bar A, Samra Y (1989) "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg, 18, p. 206-7
- Chan M, Beale D, Moorhead J (1980) "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract, 34, p. 87-8
- Damergis J, Stoker J, Abadie J (1983) "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA, 249, p. 590-1
- Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP (1992) "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol, 19, p. 621-2
- Youssef PP, Bertouch JV (1992) "Sulphasalazine induced aplastic anaemia." Aust N Z J Med, 22, p. 391-2
- Keisu M, Ekman E (1992) "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol, 43, p. 215-8
- Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ (1985) "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol, 80, p. 118-21
- Wheelan KR, Cooper B, Stone MJ (1982) "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med, 97, p. 726-7
- Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ (1985) "Thrombocytopenia and sulfasalazine." Ann Intern Med, 102, p. 277-8
- Davies GE, Palek J (1980) "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med, 140, p. 1122
- Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J (1989) "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol, 16, p. 1166-7
- Mitrane MP, Singh A, Seibold JR (1986) "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol, 13, p. 969-72
- Mechanick JI (1985) "Coombs' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med, 52, p. 667-70
- Betkowski AS, Lubin A (1993) "Sulfamethoxazole-related antiplatelet antibody." Blood, 82, p. 1683
- Gales BJ, Gales MA (1993) "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother, 27, p. 1052-4
- (2022) "Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories
- (2001) "Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc
- (2001) "Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- "Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation
- "Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals
- (2001) "Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- (2022) "Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals
Topical sulfonamides (applies to Vasosulf) hypersensitivity reactions
Major Potential Hazard, Moderate plausibility. Applicable conditions: Allergies, Asthma, HIV Infection
Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes. The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole. Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity. Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions. Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis. Sulfonamide therapy should be stopped at once if a rash develops.
References
- Johnson M, Goodwin D, Shands J (1990) "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy, 10, p. 413-16
- Hofer T, Becker EW, Weigand K, Berg PA (1992) "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol, 15, p. 262-3
- Stevenson D, Christie D, Haas J (1978) "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics, 61, p. 864-6
- Smith E, Light J, Filo R, Yum M (1980) "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA, 244, p. 360-1
- Whittington R (1989) "Toxic epidermal necrolysis and co-trimoxazole." Lancet, 2, p. 574
- Kelly W, Dooley D, Lattuada C, Smith C (1992) "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis, 14, p. 1034-9
- Horak J, Mertl L, Hrabal P (1984) "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology, 31, p. 199-200
- Gibson J (1982) "Recurrent trimethoprim-associated fixed skin eruption." Br Med J, 284, p. 1529-30
- Holdcroft C, Ellison R (1991) "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS, 5, p. 1029-42
- Steinbrecher U, Mishkin S (1981) "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci, 26, p. 756-9
- Rudra T, Webb D, Evans A (1989) "Acute tubular necrosis following co-trimoxazole therapy." Nephron, 53, p. 85-6
- Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB (1989) "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest, 95, p. 937-8
- Heer M, Altorfer J, Burger H, Walti M (1985) "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology, 88, p. 1954-7
- Pisanty S, Brayer L (1965) "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med, 20, p. 154-7
- Robson M, Levi J, Dolberg L, Rosenfeld J (1970) "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci, 6, p. 561-6
- Goadsby P, Donaghy A, Lloyd A, Wakefield D (1987) "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med, 107, p. 783-4
- Carbone L, Bendixen B, Appel G (1988) "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis, 12, p. 72-5
- Tenant-Flowers M, Boyle M, Carey D, et al. (1991) "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS, 5, p. 311-5
- Leroux JL, Ghezail M, Chertok P, Blotman F (1992) "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol, 10, p. 427
- Kanner RS, Tedesco FJ, Kalser MH (1978) "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis, 23, p. 956-8
- Losek JD, Werlin SL (1981) "Sulfasalazine hepatotoxicity." Am J Dis Child, 135, p. 1070-2
- Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D (1984) "Sulfasalazine hepatotoxicity." Am J Gastroenterol, 79, p. 401-2
- Yaffe BH, Korelitz BI (1983) "Sulfasalazine pneumonitis." Am J Gastroenterol, 78, p. 493-4
- Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS (1986) "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol, 81, p. 205-8
- Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y (1985) "Sulfasalazine pneumonitis." Am J Gastroenterol, 80, p. 343-5
- Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J (1992) "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol, 87, p. 1654-7
- Poland GA, Love KR (1986) "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med, 81, p. 707-8
- Hamadeh MA, Atkinson J, Smith LJ (1992) "Sulfasalazine-induced pulmonary disease." Chest, 101, p. 1033-7
- Williams T, Eidus L, Thomas P (1982) "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest, 81, p. 766-8
- Valcke Y, Pauwels R, Van der Straeten M (1987) "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest, 92, p. 572-3
- Taffet SL, Das KM (1983) "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci, 28, p. 833-42
- Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H (1986) "Serious complications of sulfasalazine." Dis Colon Rectum, 29, p. 201-2
- Sotolongo RP, Neefe LI, Rudzki C, Ishak KG (1978) "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology, 75, p. 95-9
- Wang KK, Bowyer BA, Fleming CR, Schroeder KW (1984) "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc, 59, p. 343-6
- Haines JD, Jr (1986) "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med, 79, 193-4,
- Faintuch J, Mott CB, Machado MC (1985) "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg, 70, p. 271-2
- Marinos G, Riley J, Painter DM, McCaughan GW (1992) "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol, 14, p. 132-5
- Namias A, Bhalotra R, Donowitz M (1981) "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol, 3, p. 193-8
- Gremse DA, Bancroft J, Moyer MS (1989) "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr, 9, p. 261-3
- Marinac JS, Stanford JF (1993) "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis, 16, p. 178-9
- Rubin R (1994) "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol, 89, p. 789-91
- Roujeau JC, Kelly JP, Naldi L, et al. (1995) "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med, 333, p. 1600-7
- Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J (1996) "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis, 34, p. 155-6
- (2022) "Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories
- (2001) "Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc
- (2001) "Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- "Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation
- "Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals
- (2001) "Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- (2022) "Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals
Topical sulfonamides (applies to Vasosulf) porphyria
Major Potential Hazard, Moderate plausibility.
Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes. Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack. The use of oral sulfonamides is considered contraindicated in patients with porphyria.
References
- (2022) "Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories
- (2001) "Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc
- (2001) "Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- "Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation
- "Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals
- (2001) "Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- (2022) "Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals
Topical sulfonamides (applies to Vasosulf) crystalluria
Moderate Potential Hazard, Low plausibility. Applicable conditions: Dehydration, Diarrhea, Vomiting
Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes. The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract. Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported. Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
References
- Robson M, Levi J, Dolberg L, Rosenfeld J (1970) "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci, 6, p. 561-6
- Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R (1988) "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med, 84, p. 791-2
- Simon D, Brosius F, Rothstein D (1990) "Sulfadiazine crystalluria revisited." Arch Intern Med, 150, p. 2379-84
- Molina J, Belenfant X, Doco-Lecompte T, et al. (1991) "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS, 5, p. 587-9
- Sasson JP, Dratch PL, Shortsleeve MJ (1992) "Renal US findings in sulfadiazine-induced crystalluria." Radiology, 185, p. 739-40
- Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE (1993) "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol, 39, p. 254-6
- Erturk E, Casemento JB, Guertin KR, Kende AS (1994) "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol, 151, p. 1605-6
- (2022) "Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories
- (2001) "Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc
- (2001) "Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- "Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation
- "Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals
- (2001) "Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- (2022) "Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals
Topical sulfonamides (applies to Vasosulf) liver disease
Moderate Potential Hazard, Low plausibility.
Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes. Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides. In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment. Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.
References
- Kowdley K, Keeffe E, Fawaz K (1992) "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology, 102, p. 2148-50
- Hofer T, Becker EW, Weigand K, Berg PA (1992) "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol, 15, p. 262-3
- Stevenson D, Christie D, Haas J (1978) "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics, 61, p. 864-6
- Horak J, Mertl L, Hrabal P (1984) "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology, 31, p. 199-200
- Steinbrecher U, Mishkin S (1981) "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci, 26, p. 756-9
- Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L (1989) "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol, 84, p. 1577-9
- Ransohoff D, Jacobs G (1981) "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology, 80, p. 816-9
- Hekster C, Vree T (1982) "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother, 31, p. 22-118
- Madsen S (1966) "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy, 11, p. 1-9
- Andreasen F, Elsborg L, Husted S, Thomsen O (1978) "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol, 14, p. 57-67
- Ortengren B, Fellner H, Bergan T (1979) "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection, 7 Suppl 4, s367-70
- Stachowska B, Senczuk W (1987) "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol, 25, p. 81-5
- Ortengren B, Magni L, Bergan T (1979) "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection, 7, s371-81
- Bergan T, Brodwall EK (1972) "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand, 192, p. 483-92
- Kremers P, Duvivier J, Heusghem C (1974) "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol, 14, p. 112-7
- Patel RB, Welling PG (1980) "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet, 5, p. 405-23
- Khan AK, Truelove SC, Aronson JK (1982) "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol, 13, p. 523-8
- Klotz U (1985) "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet, 10, p. 285-302
- Leroux JL, Ghezail M, Chertok P, Blotman F (1992) "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol, 10, p. 427
- Kanner RS, Tedesco FJ, Kalser MH (1978) "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis, 23, p. 956-8
- Losek JD, Werlin SL (1981) "Sulfasalazine hepatotoxicity." Am J Dis Child, 135, p. 1070-2
- Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D (1984) "Sulfasalazine hepatotoxicity." Am J Gastroenterol, 79, p. 401-2
- Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS (1986) "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol, 81, p. 205-8
- Poland GA, Love KR (1986) "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med, 81, p. 707-8
- Sotolongo RP, Neefe LI, Rudzki C, Ishak KG (1978) "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology, 75, p. 95-9
- Haines JD, Jr (1986) "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med, 79, 193-4,
- Marinos G, Riley J, Painter DM, McCaughan GW (1992) "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol, 14, p. 132-5
- Namias A, Bhalotra R, Donowitz M (1981) "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol, 3, p. 193-8
- Gremse DA, Bancroft J, Moyer MS (1989) "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr, 9, p. 261-3
- Rubin R (1994) "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol, 89, p. 789-91
- Schroder H, Campbell DE (1972) "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther, 13, p. 539-51
- Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W (1995) "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr, 154, p. 530-3
- (2022) "Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories
- (2001) "Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc
- (2001) "Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- "Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation
- "Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals
- (2001) "Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- (2022) "Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals
Topical sulfonamides (applies to Vasosulf) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes. Once absorbed, sulfonamides and their metabolites are eliminated by the kidney. Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance. Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine. Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks). Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.
References
- Smith E, Light J, Filo R, Yum M (1980) "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA, 244, p. 360-1
- Rudra T, Webb D, Evans A (1989) "Acute tubular necrosis following co-trimoxazole therapy." Nephron, 53, p. 85-6
- Cryst C, Hammar S (1988) "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol, 8, p. 483-8
- Robson M, Levi J, Dolberg L, Rosenfeld J (1970) "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci, 6, p. 561-6
- Goadsby P, Donaghy A, Lloyd A, Wakefield D (1987) "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med, 107, p. 783-4
- Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R (1988) "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med, 84, p. 791-2
- Carbone L, Bendixen B, Appel G (1988) "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis, 12, p. 72-5
- Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C (1990) "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron, 55, p. 233-4
- Simon D, Brosius F, Rothstein D (1990) "Sulfadiazine crystalluria revisited." Arch Intern Med, 150, p. 2379-84
- Molina J, Belenfant X, Doco-Lecompte T, et al. (1991) "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS, 5, p. 587-9
- Marques L, Silva M, Madeira E, Santos O (1992) "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron, 62, p. 361
- Hekster C, Vree T (1982) "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother, 31, p. 22-118
- Adam W, Dawborn J (1970) "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med, 19, p. 250-4
- Madsen S (1966) "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy, 11, p. 1-9
- Andreasen F, Elsborg L, Husted S, Thomsen O (1978) "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol, 14, p. 57-67
- Bergan T, Brodwall E, Vik-Mo H, Anstad U (1979) "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection, 7, s382-7
- Ortengren B, Fellner H, Bergan T (1979) "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection, 7 Suppl 4, s367-70
- Stachowska B, Senczuk W (1987) "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol, 25, p. 81-5
- Ohnhaus EE, Spring P (1975) "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm, 3, p. 171-9
- Ortengren B, Magni L, Bergan T (1979) "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection, 7, s371-81
- Bergan T, Brodwall EK (1972) "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand, 192, p. 483-92
- Adam WR, Henning M, Dawborn JK (1973) "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med, 3, p. 383-7
- Kremers P, Duvivier J, Heusghem C (1974) "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol, 14, p. 112-7
- Rieder J, Schwartz DE, Fernex M, et al. (1974) "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother, 18, p. 148-98
- Bergan T, Brodwall EK, Vik-Mo H, Anstad U (1979) "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection, 7, s382-7
- Patel RB, Welling PG (1980) "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet, 5, p. 405-23
- Vergin H, Ferber H, Zimmermann I, Neurath GB (1981) "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol, 19, p. 350-7
- Cohen M, Pocelinko R (1973) "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther, 185, p. 703-12
- Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S (1985) "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother, 28, p. 535-9
- Dwarakanath AD, Michael J, Allan RN (1992) "Sulphasalazine-induced renal failure." Gut, 33, p. 1006-7
- Marques LP, Silva MT, Madeira EP, Santos OR (1992) "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron, 62, p. 361
- Sasson JP, Dratch PL, Shortsleeve MJ (1992) "Renal US findings in sulfadiazine-induced crystalluria." Radiology, 185, p. 739-40
- Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J (1993) "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med, 233, p. 365-7
- Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE (1993) "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol, 39, p. 254-6
- Erturk E, Casemento JB, Guertin KR, Kende AS (1994) "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol, 151, p. 1605-6
- Becker K, Jablonowski H, Haussinger D (1996) "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine, 75, p. 185-94
- (2022) "Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories
- (2001) "Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc
- (2001) "Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- "Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation
- "Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals
- (2001) "Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- (2022) "Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals
Topical sulfonamides (applies to Vasosulf) urinary obstruction
Moderate Potential Hazard, Low plausibility. Applicable conditions: Urinary Retention
Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes. Once absorbed, sulfonamides are excreted and concentrated in the urine. Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur. These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine. A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
References
- Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R (1988) "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med, 84, p. 791-2
- Carbone L, Bendixen B, Appel G (1988) "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis, 12, p. 72-5
- Simon D, Brosius F, Rothstein D (1990) "Sulfadiazine crystalluria revisited." Arch Intern Med, 150, p. 2379-84
- Molina J, Belenfant X, Doco-Lecompte T, et al. (1991) "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS, 5, p. 587-9
- Marques L, Silva M, Madeira E, Santos O (1992) "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron, 62, p. 361
- Marques LP, Silva MT, Madeira EP, Santos OR (1992) "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron, 62, p. 361
- Sasson JP, Dratch PL, Shortsleeve MJ (1992) "Renal US findings in sulfadiazine-induced crystalluria." Radiology, 185, p. 739-40
- Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE (1993) "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol, 39, p. 254-6
- Erturk E, Casemento JB, Guertin KR, Kende AS (1994) "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol, 151, p. 1605-6
- (2022) "Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories
- (2001) "Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc
- (2001) "Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- "Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation
- "Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals
- (2001) "Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis
- (2022) "Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals
Topical sympathomimetics (applies to Vasosulf) BPH
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Benign Prostatic Hyperplasia, Prostate Tumor
Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate. It is important that the recommended dosages of the individual products not be exceeded.
References
- Lansche RK (1966) "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol, 61, p. 95-8
- Ellis PP (1971) "Systemic reactions to topical therapy." Int Ophthalmol Clin, 11, p. 1-11
- "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories
- "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough
- (2001) "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals
- (2001) "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough
- "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals
- (2001) "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health
- (2001) "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc
- "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals
- (2001) "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc
- (2001) "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc
Topical sympathomimetics (applies to Vasosulf) cardiovascular
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Cerebrovascular Insufficiency, Hyperthyroidism, Corneal Abrasion
Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion have been reported rarely during the use of ophthalmic and nasal sympathomimetic agents, but may be more likely if the corneal epithelium is damaged or if an excessive amount of drug is swallowed during nasal administration. Therapy with topical sympathomimetic agents should be administered cautiously in patients with corneal abrasion, sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension. The potent ophthalmic formulations (e.g., phenylephrine 2.5% or 10%) that are used for diagnostic and pre-surgical purposes should not be used in such patients. For other preparations, it is important that the recommended dosages of the individual products not be exceeded.
References
- Lansche RK (1966) "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol, 61, p. 95-8
- Ellis PP (1971) "Systemic reactions to topical therapy." Int Ophthalmol Clin, 11, p. 1-11
- "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories
- "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough
- (2001) "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals
- (2001) "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough
- "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals
- (2001) "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health
- (2001) "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc
- "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals
- (2001) "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc
- (2001) "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc
Topical sympathomimetics (applies to Vasosulf) diabetes
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use. Slight increases in blood glucose concentrations may occur with the use of these drugs. Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. It is important that the recommended dosages of the individual products not be exceeded.
References
- Lansche RK (1966) "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol, 61, p. 95-8
- Ellis PP (1971) "Systemic reactions to topical therapy." Int Ophthalmol Clin, 11, p. 1-11
- "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories
- "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough
- (2001) "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals
- (2001) "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough
- "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals
- (2001) "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health
- (2001) "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc
- "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals
- (2001) "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc
- (2001) "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc
Vasosulf drug interactions
There are 91 drug interactions with Vasosulf (phenylephrine / sulfacetamide sodium ophthalmic).
More about Vasosulf (phenylephrine / sulfacetamide sodium ophthalmic)
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.